SBH
TEVA icon

Segall Bryant & Hamill’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Segall Bryant & Hamill’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-44,698
Closed -$1.49M – 577
2017
Q2 		$1.49M Sell
44,698
-2,694
-6% -$83.4K 0.04% 332
2017
Q1 		$1.52M Buy
47,392
+800
+2% +$27.3K 0.04% 321
2016
Q4 		$1.69M Sell
46,592
-465
-1% -$18.6K 0.04% 308
2016
Q3 		$2.17M Buy
47,057
+5,000
+12% +$261K 0.06% 276
2016
Q2 		$2.11M Sell
42,057
-1,649
-4% -$87.8K 0.06% 279
2016
Q1 		$2.34M Hold
43,706
– – 0.06% 285
2015
Q4 		$2.87M Hold
43,706
– – 0.07% 273
2015
Q3 		$2.47M Buy
43,706
+36,355
+495% +$2.36M 0.06% 283
2015
Q2 		$434K Sell
7,351
-500
-6% -$30.8K 0.01% 439
2015
Q1 		$489K Hold
7,851
– – 0.01% 430
2014
Q4 		$452K Hold
7,851
– – 0.01% 435
2014
Q3 		$422K Sell
7,851
-1,050
-12% -$55.6K 0.01% 447
2014
Q2 		$467K Buy
8,901
+225
+3% +$11.5K 0.01% 445
2014
Q1 		$458K Sell
8,676
-1,030
-11% -$47.6K 0.01% 450
2013
Q4 		$389K Sell
9,706
-767
-7% -$30.2K 0.01% 478
2013
Q3 		$396K Sell
10,473
-834
-7% -$32.5K 0.01% 470
2013
Q2 		$443K Buy
+11,307
New +$440K 0.01% 415

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Segall Bryant & Hamill's TEVA Position: Q3 2017 in Review

Segall Bryant & Hamill sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q3 2017, closing a stake of 44,698 shares — an estimated $1.49M sold.

Segall Bryant & Hamill first reported a position in TEVA in Q2 2013 and held it in 17 quarters. The position peaked at $2.87M in Q4 2015. 537 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • Segall Bryant & Hamill reported no remaining Teva Pharmaceutical Industries Limited position as of Q3 2017 after selling out during the quarter.
  • Segall Bryant & Hamill sold 44,698 Teva Pharmaceutical Industries Limited shares in Q3 2017, an estimated $1.49M.
  • Segall Bryant & Hamill first reported a position in Teva Pharmaceutical Industries Limited in Q2 2013 and held it in 17 quarters.
  • Segall Bryant & Hamill's Teva Pharmaceutical Industries Limited position peaked at $2.87M in Q4 2015.
  • 537 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q3 2017.

Based on Segall Bryant & Hamill's 13F filing for Q3 2017, filed 14 Nov 2017.